Tetragon Partners GP Ltd: CELLDEX THERAPEUTICS INC (CLDX): Quarterly 13F Position History
As of Q1 2026, Tetragon Partners GP Ltd reported 312,316 shares of CELLDEX THERAPEUTICS INC (CLDX), worth $9.9M and representing 1.9% of its 13F equity book. Quarter-over-quarter share count change: + 68,516 (+28.1%) . The position first appeared in Q4 2024 and has been disclosed across 6 13F-HR filings in Pactolio's tracked window.
- 312,316Shares Held (Latest Filing)
- $9.9MReported Market Value (Latest Filing)
- 1.9%Portfolio Weight (% of 13F Equity Book)
- +68,516Quarter-over-Quarter Share Change
- +$3.3MQuarter-over-Quarter Value Change
- 316,150Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 6 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 312,316 | +68,516 | +28.1% | $9.9M | 1.9% | $31.7 |
| Q4 2025 | 243,800 | 59,800 | -19.7% | $6.6M | 1.4% | $27.2 |
| Q3 2025 | 303,600 | 12,550 | -4.0% | $7.9M | 1.1% | $25.9 |
| Q2 2025 | 316,150 | +55,150 | +21.1% | $6.4M | 1.2% | $20.4 |
| Q1 2025 | 261,000 | +69,000 | +35.9% | $4.7M | 1.5% | $18.1 |
| Q4 2024 | 192,000 | — | — | $4.9M | 1.5% | $25.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Tetragon Partners GP Ltd first disclose a CLDX position in 13F-HR filings?
Tetragon Partners GP Ltd first reported CELLDEX THERAPEUTICS INC (CLDX) on its 13F-HR filing for the period ending 2024-12-31 (Q4 2024). The position has appeared on 6 reported quarters within Pactolio's tracked window.
What was Tetragon Partners GP Ltd's most recent quarter-over-quarter share-count change in CLDX?
Between Q4 2025 and Q1 2026, Tetragon Partners GP Ltd added 68,516 shares of CLDX (+28.1%), bringing the total reported position to 312,316 shares at a market value of $9.9M.
Does the implied price-per-share represent Tetragon Partners GP Ltd's cost basis in CLDX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.